Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Izumerogant in mCRPC
NCT05124795Phase 1Terminated
- Sponsor
- Immunic Therapeutics
- Start
- Dec 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of izumerogant in metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Immunic Therapeutics. Primary endpoints: Incidence and Grade of Dose-Limiting Toxicities at 28 days and Number and Severity of Adverse Events at 6 months. Started Dec 2021; status: terminated.
02
Drugs
izumerogant
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05124795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124795.